# NorthSpring Capital Partners

> NorthSpring Capital Partners is a VC fund backing Health Care. See 17 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, Canada
- Total investments: 17
- Last investment: Jun 2024
- Lead investor: 24%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/northspring-capital-partners/
- Website: http://northspringcapitalpartners.com

NorthSpring Capital Partners is a VC fund in Cambridge focused on Health Care and Medical Device. NorthSpring Capital Partners provides risk capital to small and medium sized companies with the goal of creating value. Investments range between $250,000 and $1 million in the form of subordinated debt and/or equity across a variety of traditional industries located in Southern Ontario. NorthSpring takes a flexible approach when reviewinginvestment opportunities and tailors its investment structure to fit the unique aspects of the business.

## Contacts

5 contacts available for NorthSpring Capital Partners. Shizune tracks 1 team members at NorthSpring Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/northspring-capital-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $675k–$5M |
| Pre-Seed | $1.6M–$1.8M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 8 | 47% |
| Medical Device | 7 | 41% |
| Software | 4 | 24% |
| Medical | 3 | 18% |
| Biotechnology | 3 | 18% |

37 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 10 | 59% |
| Pre-Seed | 2 | 12% |
| Series A | 2 | 12% |
| Debt Financing | 1 | 6% |
| Venture - Series Unknown | 1 | 6% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Canada | 15 | 88% |
| United States | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Brian Hunter | President | 4 | https://shizune.co/investors/profile/brian-hunter-30c3 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mesosil | Mesosil develops responsive antimicrobial materials to prevent infection at the medical device-tissue interface, with lifetime length of effect. Our technology is ideally suited for dental restoratives and dental implant surfaces. The result is greatly improved patient outcome with no change to practitioner workflow, reducing the likelihood ofrecurrent caries and detachment of dental restorations, or peri-implant wound infection that could result in implant loss and implant revision. | $1.6M | Seed | Jun 05, 2024 |  |
| Noa Therapeutics | Noa Therapeutics is a preclinical biotech firm that is leading the way in the development of multimodal treatments. To simplify the course of care for patients in need, we developed a single, non-steroidal, small molecule with tunable efficacy | $1.6M | Pre-Seed | Mar 06, 2024 |  |
| YOURIKA | YOURIKA combines years of AI research from the University of Waterloo (Top 5 in AI) with our proprietary technology and domain expertise to make smarter and more connected learning products. This includes our own platform, ORBITS, that liberates teenage students to work smarter when learning remotely. | $2.6M | Seed | Oct 31, 2022 |  |
| Oncoustics AI | Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers. | $5M | Seed | Jul 21, 2022 |  |
| Able Innovations | Able Innovations is developing advanced medical devices to tackle the pressing problem of patient transfer in healthcare. Their technology is revolutionizing the quality of care provision - providing a safe, efficient, and dignified care experience for patients and caregivers. | $3.5M | Seed | Jun 13, 2022 |  |
| Rehabtronics | Rehabtronics is a technology development firm that focuses on solutions for physical rehab. | $1.6M | Venture - Series Unknown | Nov 18, 2021 |  |
| Mesosil | Mesosil develops responsive antimicrobial materials to prevent infection at the medical device-tissue interface, with lifetime length of effect. Our technology is ideally suited for dental restoratives and dental implant surfaces. The result is greatly improved patient outcome with no change to practitioner workflow, reducing the likelihood ofrecurrent caries and detachment of dental restorations, or peri-implant wound infection that could result in implant loss and implant revision. | $675K | Seed | Jul 13, 2021 |  |
| Workwolf | Workwolf is a Toronto-based start-up with a management team who has led 7 start-ups, had 2 successful exits, and has taken a company public with a $1.8B IPO. Workwolf CEO Erik Simins is an SME in HR who previously founded MAGNUS HRS, a staffing company now servicing over 150 enterprise customers. The technology at Workwolf solves two of the biggestpain points in employment: applicant filtration and verification, and does so by empowering users to identify better candidates faster. Winner of global awards in both 2020 and 2021 for innovation and market potential, Workwolf is ramping up for its multi-national roll-out with ManpowerGroup in September that will coincide with a $4.5M Seed financing round. | $1.8M | Pre-Seed | Dec 15, 2020 |  |
| Forcen | Forcen is a tier 1 supplier of Force/Torque sensor systems and edge intelligence to robotics OEMs. A comprehensive plug-and-play sensing network for your robot's force/torque systems. |  | Seed | Sep 16, 2020 |  |
| FluidAI Medical | FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery. | $2.7M | Seed | Apr 14, 2020 |  |

10 of 17 investments shown.

## Co-investors
- [Archangel Network of Funds](https://shizune.co/investors/profile/archangel-4de5) — VC Fund, 5 deals together
- [BDC](https://shizune.co/investors/profile/bdc-2) — VC Fund, 2 deals together
- [Creative Ventures](https://shizune.co/investors/profile/creative-ventures) — VC Fund, 2 deals together
- [Globalive](https://shizune.co/investors/profile/globalive-capital) — VC Fund, 2 deals together
- [Golden Triangle Angel Network](https://shizune.co/investors/profile/golden-triangle-angel-network) — VC Fund, 2 deals together
- [Ontario Centre of Innovation](https://shizune.co/investors/profile/oci-e51e) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Health Care Investors in Canada](https://shizune.co/investors/health-care-investors-canada)
- [Health Care VC Funds in Canada](https://shizune.co/investors/health-care-vc-funds-canada)
- [Medical Device VC Funds in Canada](https://shizune.co/investors/medical-device-vc-funds-canada)
- [Digital Media Investors in Canada](https://shizune.co/investors/digital-media-investors-canada)
- [Social Impact VC Funds in Canada](https://shizune.co/investors/social-impact-vc-funds-canada)
- [Legal VC Funds in Canada](https://shizune.co/investors/legal-vc-funds-canada)

## FAQ

### What does NorthSpring Capital Partners invest in?

NorthSpring Capital Partners invests primarily in Health Care, Medical Device and Software startups, most often at Seed and Pre-Seed stage. Most of the 17 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is NorthSpring Capital Partners's check size?

NorthSpring Capital Partners typically joins rounds of $675k–$5M at Seed and $1.6M–$1.8M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds NorthSpring Capital Partners participates in.

### How do I contact NorthSpring Capital Partners?

Public channels for NorthSpring Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at NorthSpring Capital Partners?

The team at NorthSpring Capital Partners includes Brian Hunter (President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co